Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
HRTX Heron Therapeutics Inc
IFBD Infobird Co Ltd
JACK Jack in the Box Inc
MVLY Mission Valley Bancorp
CLSD Clearside Biomedical Inc
GBRGU Goldenbridge Acquisition Ltd
CHMI-B Cherry Hill Mortgage Investment Corp
KAIIU Kismet Acquisition Two Corp
Go

Health Care : Biotechnology |
Company profile

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Closing Price
$0.428
Day's Change
-0.027 (-5.93%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.455
Day's Low
0.41
Volume
(Light)
Volume:
1,837,083

10-day average volume:
2,800,119
1,837,083

Display:

Providers:

UpdateCancel
4 providers
September 19, 2022
Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate

Shares of Virios Therapeutics Inc. tumbled 64.3% in premarket trading on Monday after the company said its experimental fibromyalgia treatment did not meet the primary endpoint in a Phase 2b clinical trial. "Overall, the efficacy data from...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.